Healthcare Industry News: Roche
News Release - August 17, 2009
Symphogen Appoints Adriann Sax Chief Business OfficerSeasoned Executive will Drive Business Development Efforts for Antibody Discovery and Expression Platforms
COPENHAGEN, Aug 17--(HSMN NewsFeed)--Symphogen A/S today announced that Adriann Sax has joined the company’s management team as Chief Business Officer.
Ms. Sax brings to Symphogen extensive experience in corporate and business development and has held several executive and management positions at leading biotechnology and pharmaceutical companies. “Adriann’s demonstrated leadership skills in the areas of strategic, operational and portfolio planning, capital raising, and alliance building and cultivation all make her a perfect fit for Symphogen at this important point in our company’s evolution,” said Kirsten Drejer, Ph.D., CEO of Symphogen.
Ms. Sax added, “I look forward to supporting Symphogen’s business objectives for its novel pipeline and antibody discovery and expression platforms. By capturing the diversity and specificity of the natural human immune response, Symphogen creates recombinant fully human monoclonal and polyclonal antibodies, with demonstrated advantages over other antibody approaches. I believe that these advantages will translate into more potent therapeutic effects in the treatment of serious diseases and will be an important asset for potential corporate partners who seek to strengthen their internal therapeutic antibody programs.”
Before Symphogen, Adriann most recently served as Executive Vice President, Corporate Strategy, Strategic Marketing and Alliances at King Pharmaceuticals. Prior to this most recent position, she served as Executive Vice President, Business Development and Strategic Planning at King, leading many successful transactions. With over 25 years of pharmaceutical experience, Adriann has held leadership roles at Merck, Bristol-Myers Squibb, Roche Laboratories and Sterling Drug, and made many important contributions in the areas of oncology, transplantation and diagnostic imaging.
Adriann is also recognized for her ongoing commitment to the professional development and advancement of women within the pharmaceutical industry. She serves as a Director on the National Advisory Board of the Healthcare Businesswomen’s Association and Foundation Associate of the Women Business Leaders of the U.S. Healthcare Foundation. In 2008, Adriann was named as one of the Top 100 Most Inspiring Leaders in the Life Sciences Industry by PharmaVoice Magazine.
Ms. Sax holds an MBA in Marketing from the Keller Graduate School of Management and a BS in Veterinary Medicine from the University of Delaware.
Symphogen is developing superior antibody therapeutics to help people with serious diseases. With its proprietary SymplexTM discovery and SympressTM manufacturing platforms, the company captures the diversity and specificity of the natural immune response in rationally designed recombinant antibody compositions. Symphogen is maturing a diversified pipeline of internal and partnered products across multiple indications including cancer and infectious disease. Symphogen is a private biopharmaceutical company with more than 70 employees, based in Copenhagen, Denmark. www.symphogen.com
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.